Absolute Configuration of (+)-Erythro-Mefloquine

  • ChemPubSoc Europe Logo
  • Author: ChemPlusChem
  • Published Date: 28 June 2013
  • Source / Publisher: ChemPlusChem/Wiley-VCH
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
thumbnail image: Absolute Configuration of (+)-Erythro-Mefloquine

Related Societies

Mefloquine (MQ), a known antimalarial drug, is commercially available as a racemate where both enantiomers have been shown to display biological differences. The (+)-MQ is more active on some Plasmodium strains, whereas the (–)-MQ is known to act as an adenosine receptor agonist; such binding is believed to be responsible for neuropsychiatric side effects such as depression and psychosis.


A number of researchers have attempted to determine the absolute configuration of erythro-mefloquine enantiomers in the past. Uwe M. Reinscheid and Christian Griesinger, Max-Planck-Institut für Biophysikalische Chemie, Göttingen, Germany, Birger Dittrich, Georg-August-Universität Göttingen, Germany, and co-workers have determined the X-ray crystal structures two mefloquine enantiomeric Mosher amides. Meanwhile, Pascal Sonnet, Université de Picardie Jules Verne, Amiens cedex, France, and colleagues reported the X-ray crystallography, CD spectroscopy, and molecular modelling of both MQ enantiomers along with their respective antimalarial activities.

In these two publications, the absolute configuration of (+)-erythro-mefloquine has been determined as (11S, 12R).


Article Views: 2280

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH